JavaScript is disabled for your browser. Some features of this site may not work without it.
2017 CVM News: Dr. Brian VanderVen's paper pinpoints a new target for tuberculosis drugs
dc.contributor.author | Office of Marketing and Communications. Media Relations | |
dc.date.accessioned | 2017-07-11T17:38:12Z | |
dc.date.available | 2017-07-11T17:38:12Z | |
dc.date.issued | 2017-06-27 | |
dc.identifier.uri | https://hdl.handle.net/1813/52037 | |
dc.description.abstract | The news item from the Cornell Chronicle is about: Dr. Brian VanderVen, assistant professor of microbiology and immunology, and colleagues at Cornell’s College of Veterinary Medicine, have discovered a key metabolic mechanism in Mycobacterium tuberculosis (Mtb) bacteria, which presents as a novel drug target for potentially treating tuberculosis. The finding is published in the journal eLife. | |
dc.language.iso | en_US | |
dc.publisher | Cornell University, College of Veterinary Medicine | |
dc.subject | Cornell University. College of Veterinary Medicine -- Periodicals. | |
dc.subject | VanderVen, Brian | |
dc.subject | Roberts, Lauren Cahoon | |
dc.subject | Cornell Chronicle | |
dc.title | 2017 CVM News: Dr. Brian VanderVen's paper pinpoints a new target for tuberculosis drugs | |
dc.title.alternative | New discovery holds potential as tuberculosis drug | |
dc.type | article |